Crystalline Nanoparticle Inhalation for Lung-Targeted Antifungal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing itraconazole drugs have limited lung exposure and cause adverse reactions due to systemic administration, with no commercially available inhalation formulations for pulmonary fungal infections.
Innovation Solution
Development of an antifungal inhalation formulation comprising crystalline nanoparticles of triazole antifungal drugs, such as itraconazole or posaconazole, with specific additives like oleic acid and glycine, and a preparation method involving high-pressure homogenization to enhance stability and lung targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If itraconazole is administered orally or systemically, then antifungal effect is achieved, but lung exposure is limited and systemic adverse reactions occur
Solution Approach 1:
The patent segments the drug delivery system by developing inhalation formulations that target the lung cavity directly, separating the local therapeutic action in the lungs from systemic circulation. This allows high concentration of antifungal drug in the lung cavity while minimizing systemic exposure and associated adverse reactions.
Solution Approach 2:
The patent applies local quality by creating formulations with high drug concentration specifically in the lung cavity through inhalation administration. The crystalline nanoparticle formulation ensures localized delivery to the respiratory tract, providing intensive antifungal action where needed while reducing systemic side effects.
2Reliability
If triazole antifungal drug is formulated as crystalline nanoparticles, then lung targeting is enhanced, but formulation complexity increases
Solution Approach 1:
The patent changes the physical parameter of the drug by formulating it as crystalline nanoparticles with specific size ranges (10-1000 nm). This parameter change enhances lung targeting efficiency through improved aerosolization and deposition in the respiratory tract, while the use of conventional excipients keeps the overall formulation complexity manageable.
Solution Approach 2:
The patent creates composite materials by combining the triazole antifungal drug with excipients such as oleic acid, glycine, surfactants, and stabilizers in a crystalline nanoparticle formulation. This composite approach improves lung targeting and stability while maintaining formulation feasibility through well-established pharmaceutical ingredients.
3Manufacturing precision
If high-pressure homogenization is used to prepare crystalline nanoparticles, then particle size is reduced and stability is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by conducting high-pressure homogenization early in the manufacturing process to create crystalline nanoparticles with controlled size distribution before subsequent formulation steps. This preliminary particle size control ensures stability and lung targeting efficiency, while the use of standard homogenization equipment keeps the process relatively simple.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves high lung concentration with reduced systemic exposure, improving treatment efficacy for pulmonary fungal infections while minimizing systemic side effects.
Implementation Method 1
performing high-pressure homogenization on an initial suspension of a triazole antifungal drug, during which heating to 40° C. to 90° C. and then cooling to room temperature are performed
Implementation Method 2
obtain a suspension containing crystalline nanoparticles of the triazole antifungal drug
Implementation Method 3
the surfactant is one or more selected from the group consisting of macrogol 15 hydroxystearate, glycocholic acid, oleic acid, poloxamer, lecithin, Tween 80, and vitamin E polyethylene glycol succinate
Implementation Method 4
an optional steric stabilizer
Data Source
AI summary
The present disclosure provides an antifungal drug inhalation formulation, comprising: crystalline nanoparticles of a triazole antifungal drug. The present disclosure further provides a preparation method and use of the antifungal drug inhalation formulation.